Research & Development
Pipeline
Asceneuron aims to address high unmet medical needs in neurodegenerative proteinopathies such as Alzheimer’s and Parkinson’s disease. Our R&D pipeline is composed of innovative small-molecule therapeutics which readily enter the human brain and are aimed at preventing disease progression in Alzheimer’s and Parkinson’s disease.
* Partenered with Ferrer
AD: Alzheimer's disease
LBD: Lewy Body Dementia
FTD: Frontotemporal dementia
PDD: Parkinson's disease dementia
PSP: Progressive Supranuclear Palsy
About ASN90
ASN90 (formerly labelled as ASN120290 or ASN-561) is an in-house developed OGA inhibitor which has been outlicensed to our partner Ferrer for the orphan tau-related disease, progressive supranuclear palsy (PSP).
ASN90 received orphan drug designations by the US FDA and the European EMA for the treatment of PSP. The molecule has completed three clinical studies in healthy volunteers including a randomized, double-blind, placebo-controlled phase I study to assess its safety and tolerability of single and multiple doses in healthy young and elderly volunteers and a human positron emission tomography (PET) CNS target engagement study.
Asceneuron is exploring further potential indications for ASN90.
About ASN51
Asceneuron’s next generation OGA inhibitor ASN51 has been awarded USD 2.2 million from the Alzheimer’s Drug Discovery Foundation for a first in human Phase I study.
ASN51 has completed three Phase I clinical studies in healthy volunteers and has defined single and multiple dose target engagement using O-GlcNAcase positron emission tomography imaging and a pharmacodynamic peripheral blood mononuclear cell response assay to quantify protein O-GlcNAcylation. Data support daily dosing of ASN51 and Alzheimer’s disease as a first indication with planned Phase 2 entry in the second half of 2024.